25 shares encounter waist cut! The heat of this once popular plate has dropped sharply

category:Finance
 25 shares encounter waist cut! The heat of this once popular plate has dropped sharply


The agency believes that since October, with the third quarter performance, the pharmaceutical industry has continued to adjust. In particular, the release of vaccine research results in November has brought clarity to the global epidemic situation expectation and intensified the industrys callback. However, in the medium and long term, the leading enterprises in the subdivided fields with certain prosperity will not be afraid of adjustment. Leading companies in high barrier fields such as innovative pharmaceutical equipment and CXO (pharmaceutical R & D and production outsourcing) are expected to usher in layout opportunities.

25 pharmaceutical stocks were cut off

Wind data showed that as of November 24, a total of 25 pharmaceutical stocks had their latest share prices retreated more than 50% from the years high, most of which came from the two major segments of medical devices and biological products.

Share prices of 25 pharmaceutical stocks cut back from the years high

Affected by the global spread of the new crown epidemic, many companies in the medical device industry have seen explosive growth this year, driving the companys share price up.

In the first three quarters of this year, the company achieved a net profit of 582 million yuan, a year-on-year increase of more than 10 times. The company said that this years performance growth is mainly due to the increase in sales of new crown testing products. Driven by the performance, the stock price of shuoshi biological rose continuously in the first half of this year, once reaching 710% in the year.

But since August, the share price of shuoshi has peaked and fallen. As of the end of November 24, the share price of shuoshi biological has retreated 57% from the years high, but still maintained a year-on-year increase of more than 250%.

Daily trend of shuoshi biology

The novel coronavirus vaccine is the absolute leader from 6 to July this year. Watson bio share price has risen by nearly 100% in the past two months, thanks to a new coronavirus mRNA vaccine developed by the company and its partners in June.

But after the stock price set a high in early August, Watsons share price went down sharply. As of November 24, Watsons share price had retreated 54% from its high point in more than three months, and its cumulative gain during the year narrowed to 35%.

Daily trend of Watson biology

In addition, the current stock prices of star pharmaceutical stocks, such as Tibet pharmaceutical, Lianhuan pharmaceutical and Kanghua biology, have retreated by more than 50% from the peak of the year.

The leader of subdivided field looks forward to the opportunity of layout

A number of securities companies have recently released investment prospects for the pharmaceutical industry in 2021. Looking forward to next year, institutions generally mentioned high-quality track, believing that the pharmaceutical industry with high barriers such as innovative drugs is still a medium and long-term high-quality track, and the relevant first-line core assets still have high allocation value.

Huatai Securities said that the innovative medicine industry chain and optional medical consumption belong to the medium and long-term high-quality track, and individual stocks adhere to the first-line leading white horse and select the opportunity to allocate the ultra falling target. In 2021, we should focus on the following aspects: first, the price drop of the national medical insurance negotiation and the exclusive varieties negotiation of the conventional catalog may be too large, so it is suggested to pay attention to the large pharmaceutical enterprises with deep pipelines and strong sales capacity; second, the regional centralized purchase of medical devices is expected to be normalized, but it is judged that the price drop is limited, so we are optimistic about innovative consumables and customized consumables. CITIC Securities believes that innovation and policy changes have led to significant growth in the pharmaceutical sector in recent years, among which the layout of high-quality track is becoming more and more important. Under the overestimation value, the investment of medicine pays more attention to long-distance running. Next year, the medical sector will continue to show structural opportunities. On the one hand, the leading companies in the market, such as innovative drugs, biological medicine, medical devices, CXO, ICL, retail, medical beauty and so on, are enjoying the dividend policy continuously, and the advantages will be more prominent. On the other hand, the traditional Chinese medicine with resource endowment and part of the wave of Internet plus medical are also in the forefront. The current value of the enterprise is still undervalued, and its fundamentals are expected to improve gradually in the future. Source: Yang Qian, editor in charge of Shanghai Securities News_ NF4425

Huatai Securities said that the innovative medicine industry chain and optional medical consumption belong to the medium and long-term high-quality track, and individual stocks adhere to the first-line leading white horse and select the opportunity to allocate the ultra falling target. In 2021, we should focus on the following aspects: first, the price drop of the national medical insurance negotiation and the exclusive varieties negotiation of the conventional catalog may be too large, so it is suggested to pay attention to the large pharmaceutical enterprises with deep pipelines and strong sales capacity; second, the regional centralized purchase of medical devices is expected to be normalized, but it is judged that the price drop is limited, so we are optimistic about innovative consumables and customized consumables.

CITIC Securities believes that innovation and policy changes have led to significant growth in the pharmaceutical sector in recent years, among which the layout of high-quality track is becoming more and more important. Under the overestimation value, the investment of medicine pays more attention to long-distance running.

Next year, the medical sector will continue to show structural opportunities. On the one hand, the leading companies in the market, such as innovative drugs, biological medicine, medical devices, CXO, ICL, retail, medical beauty and so on, are enjoying the dividend policy continuously, and the advantages will be more prominent. On the other hand, the traditional Chinese medicine with resource endowment and part of the wave of Internet plus medical are also in the forefront. The current value of the enterprise is still undervalued, and its fundamentals are expected to improve gradually in the future.